FNCH Description — Finch Therapeutics Group Inc
Finch Therapeutics Group is a clinical-stage microbiome therapeutics company utilizing its Human-First Discovery platform to develop a class of orally administered biological drugs. Co. is developing therapeutics designed to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. Co.'s Human-First Discovery platform uses reverse translation to identify diseases of dysbiosis and to design microbiome therapeutics that address them. Co.'s primary product candidate, CP101, is an orally administered microbiome therapeutic in development for the prevention of recurrent Clostridioides difficile infection.